Skip to Content
Merck
CN

936499

3-Pyridinecarboxylic acid, 6-[4-[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-5-yl]-1-piperazinyl]-

≥95%

Synonym(s):

6-[4-[2-(2,6-Dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-5-yl]-1-piperazinyl]-3-pyridinecarboxylic acid

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C23H21N5O6
CAS Number:
2633591-27-0
Molecular Weight:
463.44
UNSPSC Code:
12352106
NACRES:
NA.22

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

3-Pyridinecarboxylic acid, 6-[4-[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-5-yl]-1-piperazinyl]-, ≥95%

InChI

1S/C23H21N5O6/c29-19-6-4-17(20(30)25-19)28-21(31)15-3-2-14(11-16(15)22(28)32)26-7-9-27(10-8-26)18-5-1-13(12-24-18)23(33)34/h1-3,5,11-12,17H,4,6-10H2,(H,33,34)(H,25,29,30)

InChI key

MZYKMQYHJGPMEI-UHFFFAOYSA-N

SMILES string

O=C(O)C1=CN=C(C=C1)N2CCN(C3=CC=C4C(=O)N(C(=O)C4=C3)C5C(=O)NC(=O)CC5)CC2

assay

≥95%

form

powder or crystals

color

light yellow to dark yellow

storage temp.

2-8°C

Quality Level

100

Legal Information

PROTAC is a registered trademark of Arvinas Operations, Inc., and is used under license
PROTAC® is a registered trademark of Arvinas Operations, Inc., and is used under license.

Application

This is a functionalized von-Hippel-Lindau (VHL) ligand with a terminal hydroxyl group. Allows rapid conjugation with many linkers containing active leaving groups. A basic building block for development of a protein degrader library.

Technology Spotlight:

Degrader Building Blocks for Targeted Protein Degradation

Protein Degrader Building Blocks

Other Notes

  1. Targeted Protein Degradation by Small Molecules
  2. Destruction of DNA-Binding Proteins by Programmable Oligonucleotide PROTAC (O′PROTAC): Effective Targeting of LEF1 and ERG
  3. Small-Molecule PROTACS: New Approaches to Protein Degradation
  4. Targeted Protein Degradation: from Chemical Biology to Drug Discovery
  5. Impact of linker length on the activity of PROTACs

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000503611
0000503611
0000309340
0000289940
0000289940

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Jingwei Shao et al.
Advanced science (Weinheim, Baden-Wurttemberg, Germany), 8(20), e2102555-e2102555 (2021-08-17)
DNA-binding proteins, including transcription factors (TFs), play essential roles in various cellular processes and pathogenesis of diseases, deeming to be potential therapeutic targets. However, these proteins are generally considered undruggable as they lack an enzymatic catalytic site or a ligand-binding
Daniel P Bondeson et al.
Annual review of pharmacology and toxicology, 57, 107-123 (2016-10-13)
Protein homeostasis networks are highly regulated systems responsible for maintaining the health and productivity of cells. Whereas therapeutics have been developed to disrupt protein homeostasis, more recently identified techniques have been used to repurpose homeostatic networks to effect degradation of
Kedra Cyrus et al.
Molecular bioSystems, 7(2), 359-364 (2010-10-06)
Conventional genetic approaches have provided a powerful tool in the study of proteins. However, these techniques often preclude selective manipulation of temporal and spatial protein functions, which is crucial for the investigation of dynamic cellular processes. To overcome these limitations
Momar Toure et al.
Angewandte Chemie (International ed. in English), 55(6), 1966-1973 (2016-01-13)
The current inhibitor-based approach to therapeutics has inherent limitations owing to its occupancy-based model: 1) there is a need to maintain high systemic exposure to ensure sufficient in vivo inhibition, 2) high in vivo concentrations bring potential for off-target side effects, and 3) there is
Philipp M Cromm et al.
Cell chemical biology, 24(9), 1181-1190 (2017-06-27)
Traditional pharmaceutical drug discovery is almost exclusively focused on directly controlling protein activity to cure diseases. Modulators of protein activity, especially inhibitors, are developed and applied at high concentration to achieve maximal effects. Thereby, reduced bioavailability and off-target effects can

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service